Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications

Table 1 Concomitant use of proton-pump inhibitors, H2-receptor antagonists or mucoprotective drugs in patients taking low-dose aspirin

Drug name	Number of prescriptions	Percentage of prescriptions with combination therapy to total aspirin prescriptions (%)
H2RA	36	0.12a
Oral PPIs	708	2.36
Pantoprazole	342	1.14
Esomeprazole	157	0.52
Omeprazole	121	0.40
Rabeprazole	85	0.28
Lansoprazole	3	0.01
i.v. PPIs	139	0.46
Pantoprazole sodium	132	0.44
Omeprazole sodium	7	0.02
MPs	120	0.40c
Hydrotalcite	43	0.14
Teprenone	33	0.11
Marzulene-S	25	0.083
Sucralfate	11	0.037
Gefarnate	5	0.017
Rebamipide	3	0.010
Misoprostol	0	0
PPI/MPs	36	0.12
Teprenone	11	0.037
Hydrotalcite	9	0.030
Rebamipide	5	0.017
Marzulene-S	4	0.013
Gefarnate	4	0.013
Sucralfate	3	0.010
Misoprostol	0	0

^aP < 0.05 vs oral proton-pump inhibitors (PPIs) plus i.v. PPIs;

^cP < 0.05 vs oral PPIs plus i.v. PPIs. MPs: Mucoprotective drugs; H2RA: H2-receptor antagonists.

Table 2 Pharmacoeconomic indices of mucoprotective drugs for outpatients in 2011

Drug name	Total dose (g)	DDD (g)	DDDs	Overall expenditure (CNY)	Daily expenditure (CNY)
Gefarnate	14 252	0.15	95 013	312 000	3.3
Hydrotalcite chewable tablet	282 842	3	94 280	557 000	7.4
Teprenone	11 345	0.15	75 633	380 000	5.0
Sucralfate oral suspension	459 648	8	57 456	444 000	7.7
Marzulene-S	89 880	2	44 940	250 000	5.6
Rebamipide	11 195	0.3	37 316	214 000	5.8
Sucralfate chewable tablet	13 950	4	3488	3600	1.0

MPs: Mucoprotective drugs; DDD: Defined daily dose; CNY: China Yuan.